FAQs about improving risk mitigation by challenging host cell protein assays
One of the major challenges of producing a generic anti-host-cell-protein (HCP) antibody is achieving enough coverage in a broad range of sample types. Almost every bioprocess is unique in some way, which means that the subpopulation of HCP present can also be unique.
Whether your HCP detection is outsourced or managed in-house, learn how to find the data and security of supply you need for efficient drug development.
Download this FAQ to learn about challenging your current HCP risk management strategy, courtesy of Cytiva.
